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BIG PHARMA TAKES ON MARIJUANA LEGALIZATION:
THE SYNTHETIC MARIJUANA VS. BOTANICAL
MARIJUANA PARADOX
INTRODUCTION
As legalization of marijuana spreads across the U.S., stigmas related to the
drug seem to be declining. In 2016, California, Nevada, and Massachusetts
passed measures legalizing marijuana for recreational use and sale; while
Florida, North Dakota and Arkansas legalized the use of only medical
marijuana. 1 The passage of these new laws brought the total number of states
in which marijuana is legal in some form to 29; 7 states have legalized
recreational use of marijuana, and 22 states have legalized only the medical use
of marijuana. 2
With marijuana remaining an illegal, Schedule I drug at the federal level,
many legal questions and oddities surround the implications of federal law on
state marijuana legalization. One point of apparent inconsistency is that while
botanical marijuana continues to be highly disputed, synthetic versions of
marijuana are legally produced and marketed nationwide by Big Pharma
corporations. 3 As the door continues to open for marijuana as a legal medical
alternative, Big Pharma may be faced with a significant competitive adversary.
There is some evidence to suggest that Big Pharma will respond by using its
deep pockets not only to prevent legalization, but also to prevent research that
would inform consumers of the beneficial effects of botanical marijuana vs. its
synthetic counterpart.
I.

BACKGROUND ON SYNTHETIC MARIJUANA

The term “synthetic marijuana” may call to mind illegal drugs like “K2”
and “Spice,” substances that combine a variety of chemicals to try and mimic
the effects of Tetrahydrocannabinol (THC), the main psychoactive ingredient

1
David Crary,Marijuana legalization pulls big victories on Election Night 2016,THE CANNABIST (Nov. 9,
2016, 8:51 AM), http://www.thecannabist.co/2016/11/09/marijuana-legalization-win-polls-election-2016/
67176/.
2
State Marijuana Laws in 2017 Map, GOVERNING MAGAZINE, http://www.governing.com/govdata/state-marijuana-laws-map-medical-recreational.html (last updated Sep 14, 2017).
3
See Nanette Porter, Three Different Cannabinoid-Based Medicines Approved by the FDA, MEDICAL
JANE (May, 1, 2017), https://www.medicaljane.com/2017/05/01/the-3-cannabis-based-medicines-approved-bythe-fda/
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in marijuana. 4 These man-made drugs are illegal and commonly recognized as
dangerous, and though they are referred to as “synthetic marijuana,” they are
distinct substances from the synthetic marijuana products produced by Big
Pharma corporations. The legal synthetic marijuana drugs produced by
pharmaceutical companies actually contain THC, as opposed to a barrage of
chemicals meant to copy THC; thus, these legal synthetic marijuana drugs are,
in theory, more similar to the plant they seek to imitate. 5
Synthetic marijuana began being produced by pharmaceutical companies in
the U.S. in 1980, when the National Cancer Institute experimented with pills
containing chemically created THC. 6 The pills were given the generic name
“dronabinol,” a term that would come to encompass other similar products
engineered in the decades to come. 7 The FDA began regulating the first legal
synthetic marijuana drug in 1985, with the release of brand-name Marinol. 8
Marinol was originally designated as a Schedule II drug available to cancer
patients suffering the detrimental side effects of chemotherapy, but in 1999
was downgraded to a Schedule III drug, thus increasing its availability. 9
Marinol is used to treat the same symptoms as medical marijuana, and is
prescribed to patients who would be otherwise eligible for a medical marijuana
recommendation. 10 Since the release of Marinol over 30 years ago, several
other synthetic marijuana drugs have come on the market. Some incorporate
cannabinoids other than THC that are also found in marijuana, like cannabidiol
(CBD). 11 Examples include Sativex, a mouth spray containing THC and CBD,
and Cesamet (generically “nabilone”), containing CBD. 12 It seems paradoxical
that drugs like these, which contain elements of marijuana and serve the same
purported purpose, are designated as Schedule II and III while botanical
marijuana remains Schedule I.

4
Andrea Real, What Is Synthetic Marijuana And How Does It Compare To Traditional Marijuana,
HUFFINGTON POST (Sept. 9, 2013, 5:40 PM), http://www.huffingtonpost.com/2013/09/11/synthetic-marijuana_
n_3908171.html.
5
See Andrew Renehan, Clearing the Haze Surrounding State Medical Marijuana Laws: A Preemption
Analysis and Proposed Solutions, 14 HOUS. J. HEALTH L. & POL’Y 299, 306.
6
Id.
7
Id.
8
Id.
9
Id. at 307.
10
Id.
11
10 Pharmaceutical Drugs Based on Cannabis (Nov. 27, 2013, 10:44 AM),
https://medicalmarijuana.procon.org/view.resource.php?resourceID=000883.
12
Id.

PICKLE GALLEYFINAL

2018]

2/20/2018 8:52 AM

BIG PHARMA AND MARIJUANA LEGALIZATION

129

Most recently, the drug Syndros became commercially available in the
U.S., as a Schedule II substance. 13 Syndros is a THC dronabinol substance like
Marinol, except that it is marketed in liquid form rather than a pill. 14 The
drama surrounding the approval and release of Syndros raises questions about
Big Pharma’s role and motivations in a burgeoning legal marijuana industry.
II.

BIG PHARMA THREATENED: INSYS, SYNDROS, AND THE 2016 ELECTION

Syndros’ release is notable because of the drug’s connection to lobbying
efforts during the 2016 election. The synthetic marijuana compound is
marketed by Insys Therapeutics, a pharmaceutical company that also recently
made headlines when it faced multiple investigations into its sale of a
dangerous opioid spray. 15 Insys is based in Arizona, and was heavily involved
in the state’s last election—Insys donated $500,000 to Arizonians for
Responsible Drug Policy, an organization opposing a ballot measure that
would have legalized recreational marijuana use in the state. 16 Insys’ donation
accounted for 10% of all donations received by the organization. 17 What’s
more, the donation was one of the largest individual contributions to an antilegalization campaign in history. 18 The effect of this considerable donation is
clear: Arizona’s marijuana legalization measure was the only one of its kind to
fail at the polls in 2016. 19
This sizable contribution aroused suspicions about Insys’ possible ulterior
motives, particularly when in March 2017, it was announced that the DEA had
approved the production of Syndros, a synthetic formulation of THC that
would be used to treat the same symptoms as traditional marijuana. 20 Those
supporting legalization speculated that Insys was attempting “to kill a non-

13
Douglas W. House, Insys launches Syndros in U.S., SEEKING ALPHA (Jul. 31, 2017, 11:30 AM),
https://seekingalpha.com/news/3283371-insys-launches-syndros-u-s
14
Id.
15
Ken Alltucker, Former executives of Chandler company face investigations over opioid spray,
patient deaths, AZ CENTRAL (Jun. 23, 2017, 9:29 PM), http://www.azcentral.com/story/money/business/
health/2017/06/24/legal-troubles-chandler-insys-opioid-fentanyl-deaths-doctor-bribes-accusations/416645001/.
16
Christopher Ingraham, A pharma company that spent $500,000 trying to keep pot illegal just got DEA
approval for synthetic marijuana, WASHINGTON POST (Mar. 24, 2017), https://www.washingtonpost.com/
news/wonk/wp/2017/03/24/a-pharma-company-that-spent-500000-trying-to-keep-pot-illegal-just-got-deaapproval-for-synthetic-marijuana/?utm_term=.f174164d0f02.
17
Id.
18
Ricardo Baca, Marijuana’s Biggest Enemy Is Not Jeff Sessions- It’s Big Pharma, ESQUIRE (Mar. 29,
2017), http://www.esquire.com/lifestyle/health/a54160/big-pharma-against-legal-weed/.
19
Id.
20
Ingraham, supra note 16.
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pharmaceutical market for marijuana in order to line their own pockets.” 21 It is
undoubtedly ironic that a company which said it “firmly believes in the clinical
benefits of cannabinoids” would so vigorously campaign against the
cannabinoid rich plant on which its synthetic version is directly based. 22
III. SYNTHETIC MARIJUANA VS. BOTANICAL MARIJUANA—WHICH IS BETTER
FOR PATIENTS?
Comments by Insys spokesmen imply that Syndros, and other synthetic
marijuana products, are in some way superior to traditional marijuana, in the
categories of both effectiveness and safety. 23 Though research on the effects of
botanical marijuana is somewhat sparse, evidence does seem to indicate that
the plant is as good as, if not better than, its synthetic counterparts. 24
The main distinction is that while synthetic marijuana drugs marketed by
pharmaceutical companies isolate one cannabinoid, like THC or CBD,
botanical marijuana contains over 525 known components that the plant’s
proponents argue have a cumulative effect that cannot be achieved by THC or
CBD alone. 25 The effectiveness of traditional marijuana depends on its specific
strain, maturity, and several other variables, and many believe that synthetic
marijuana cannot accurately copy it. 26 Additionally, many patients are
unsatisfied with the effects of synthetic products, like Marinol. 27 45% of
patients who were prescribed Marinol reported negative side effects, and
stopped using the drug after completing only one round of the prescription. 28
Also potentially significant is the difference in ingestion. Synthetic
marijuana is in pill or liquid form while botanical marijuana is traditionally
smoked for maximum effectiveness. Though smoking has its naysayers, there
is some evidence that smoking marijuana might be superior to consuming it. 29
Smoking’s main advantage is that patients are in complete control of the
amount of THC they are inhaling, and can take in as little or as much as they
21

Id.
Id.
23
Id.
24
See Moira Gibbons, The Cannabis Conundrum: Medication v. Regulation, 24 HEALTH LAW 1 (2011).
25
Elena Quattrone, The “Catch-22” of Marijuana Legalization, 22 B.U. J. SCI. & TECH. L. 299, 303-04
26
William Vertes & Sarah Barbantini, Caught in the Crossfire: The Dilemma of Marijuana
“Medicalization” for Health Care Providers, 58 WAYNE L. REV. 103, 114 (2012).
27
Debra Borchardt, Cannabis Drug Marinol To Get Reboot In Chewing Gum, FORBES (Mar. 28, 2017,
9:00 AM), https://www.forbes.com/sites/debraborchardt/2017/03/28/cannabis-drug-marinol-to-get-reboot-inchewing-gum/#57f551326029.
28
Id.
29
Nathan Seppa, Not Just a High, SCIENCE NEWS, Vol. 177 No. 13, Jun. 19, 2010, at 17.
22
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want. 30 In contrast, with pills, patients must take a set amount of THC that may
not be fully necessary to relieve their symptoms. 31 Some researchers also
believe that smoking marijuana is more therapeutic overall, and better relieves
the symptoms for which medical marijuana is prescribed. 32 Conflicting studies
exist on this subject, but not very many modern studies have been conducted. 33
Botanical marijuana is also, generally, cheaper than synthetic marijuana.
Drugs like Marinol are sold for $18 per 5 mg capsule, the equivalent of $3,600
per gram. 34 In contrast, botanical marijuana can be obtained for $15 a gram,
though potency and price of the plant can vary. 35 For patients without
insurance, legal botanical marijuana provides an affordable option to relieve
their symptoms. 36
The problem is that the true effects of botanical marijuana are not wellresearched, since it remains a Schedule I drug at the federal level. 37
Researchers must get the approval of 4 federal agencies before conducting
research, and can only experiment with “research-grade” marijuana, which
does not necessarily have the same beneficial effects as other available
strains. 38 The lack of concrete medical evidence on botanical marijuana’s
benefits makes it easier for Big Pharma companies to argue that their synthetic
marijuana products are better and safer for patients, despite plausible theories
to the contrary.
Lobbying efforts like those of Insys in Arizona work to prevent the
possibility of botanical marijuana being downgraded from a Schedule I
substance, and thus prevent the possibility of further research into the plant’s
effectiveness. By the same token, Insys and similar companies do not have to
show that synthetic marijuana is actually more effective than botanical
marijuana at treating the same symptoms because there is a lack of evidence
that says otherwise. With their significant resources and virtual monopoly on
accepted research, pharmaceutical companies could make it nearly impossible
for consumers to realize the potential benefits of botanical marijuana, let alone
have the choice to legally obtain it.
30
31
32
33
34
35
36
37
38

Id.
Id.
Marijuana Research, SCIENTIFIC AMERICAN, Vol. 291 No. 6, Dec. 2004, at 8.
Gibbons, supra note 23, at 4.
Id.
Id.
Id.
Marijuana Research, supra note 31, at 8.
Quattrone, supra note 24, at 315.
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IV. BIG PHARMA’S EFFECT ON MARIJUANA’S FUTURE
The actions of Insys in the 2016 election suggest that Big Pharma
companies have an incentive to fight hard for their piece of an industry which
is gaining public acceptance. Insys is a relatively small company compared to
other Big Pharma giants, but it nonetheless showed significant political
influence, which raises questions about the potential influence of larger
companies that also produce synthetic marijuana products, like GW
Pharmaceuticals. 39 Though companies claim good intentions in campaigning
against a potentially dangerous substance, what corporations like Insys are
really doing is restricting what could be a cheaper and more effective treatment
for their consumers’ medical conditions. Big Pharma companies want
botanical marijuana to remain illegal because it is financially beneficial to
them, not because synthetic marijuana is decidedly better for patients. 40
Big Pharma will have to be careful in drawing a line between its synthetic
marijuana products and the botanical alternative—otherwise, Big Pharma
companies could end up contributing to the declassification of the plant by
proving the medical benefits of its elements. 41 The paradox may only extend so
far until it becomes clear that synthetic marijuana is substantially similar to
botanical marijuana, but perhaps not as useful or cost-effective. Though Big
Pharma corporations could launch into botanical production were marijuana
legal nationwide, this is not the best outcome for pharmaceutical companies
because anyone with a dirt patch in their backyard could theoretically compete.
If Big Pharma companies like Insys are going to continue to lobby against
marijuana legalization, they should have to prove that their products are
actually better and safer, not just legal because of a loophole.
KATHARINE PICKLE ∗

39
See Insys Therapeutics’ Undervalued Cannabis Pipeline, SEEKING ALPHA (Jun. 14, 2017),
https://seekingalpha.com/article/4081423-insys-therapeutics-undervalued-cannabis-pipeline (discussing Insys’
current valuation as compared to GW Pharmaceuticals [with their synthetic marijuana drug Sativex], and how
Syndros might increase the company’s market cap)
40
Andre Bourque, Is Big Pharma for or Against Legalizing Medical Marijuana? Maybe Both.,
ENTREPRENEUR (Aug. 8, 2017), https://www.entrepreneur.com/article/297984.
41
Id.
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